Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
Company to host a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical study
BOSTON & DAEJEON, South Korea – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ORM-1153, a CD123-GSPT1 DAC. Orum plans to initiate a first-in-human Phase 1 study of ORM-1153 in patients with relapsed or refractory acute myeloid leukemia (AML) and other hematologic malignancies by the end of 2026.
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule, we believe ORM-1153 has the potential to improve treatment efficacy and tolerability for patients with severe hematologic malignancies.”
ORM-1153 uses Orum’s TPD²® approach to deliver a GSPT1 degrader payload to CD123-expressing cells, enabling targeted degradation of GSPT1. In preclinical studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, ORM-1153 demonstrated broad activity across AML models, including activity in primary AML patient samples and TP53-relevant models, as well as low-dose in vivo activity and favorable repeat-dose tolerability.
The first-in-human Phase 1 study will assess the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ORM-1153 in patients with relapsed or refractory AML and other hematologic malignancies. The multicenter study is expected to enroll approximately 42 patients initially at U.S. clinical sites, with potential expansion to other regions.
Orum will host a conference call on Monday, August 24, at 7:00 a.m. KST (Sunday, August 23, at 6:00 p.m. EDT) to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical study. Conference call details are available at https://www.orumrx.com/events.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²) with the precision of antibody targeting to develop the next generation of degrader-antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum’s novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Daejeon, South Korea, and Lexington, MA, US. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential therapeutic value of ORM-1153 and Orum’s TPD² approach; the expected initiation, timing, design, enrollment, conduct, and results of clinical trials of ORM-1153; the projected number of patients and the location of clinical trial sites; the successful translation of preclinical findings into clinical results; the potential indications for ORM-1153; the potential for ORM-1153 to address unmet medical needs in AML or other hematologic malignancies; the advancement of Orum’s GSPT1-directed TPD² programs; and the development of additional novel degrader payloads and their potential benefits, are forward-looking statements.
These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, enrollment challenges, or negative results; competition from alternative therapies; risks related to regulatory review and approval; risks related to third-party manufacturing and development activities; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this release speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in AML and the Potential for Improved Efficacy and Tolerability
ORM-1153, with optimized antibody and linker design, demonstrates improved pharmacology, low-dose in vivo activity, and favorable repeat-dose tolerability
Data show activity across primary acute myeloid leukemia (AML) patient samples and retained activity in TP53-relevant models, indicating the potential for broad activity
Together, the AACR data support continued advancement of ORM-1153 toward clinical development, with a regulatory submission expected in the second half of 2026
BOSTON & DAEJEON, South Korea - Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of new preclinical data for ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload, in development for the treatment of AML and other CD123-positive hematological malignancies. The data were presented in two posters at the American Association for Cancer Research® (AACR) Annual Meeting 2026.
“These data show strong preclinical activity and the potential for a differentiated safety and tolerability profile, supporting the advancement of ORM-1153 as a next-generation CD123-targeting degrader-antibody conjugate for acute myeloid leukemia,” said Chad May, Ph.D., Chief Scientific Officer of Orum. “Our approach combines a proprietary CD123-antibody and novel GSPT1-targeted protein degrader with the goal of achieving greater selectivity than conventional cytotoxic antibody-drug conjugates. We believe this strategy can enable more effective and better-tolerated therapies for patients with AML.”
The first poster (Abstract Number: 1824) highlights how ORM-1153 was engineered with a proprietary CD123-antibody designed for enhanced internalization and reduced Fc-gamma receptor interactions, together with a linker optimized for plasma stability, an approach intended to improve delivery, reduce off-target and immune cell engagement, and support favorable pharmacologic properties. Consistent with that design, ORM-1153 showed strong preclinical anti-leukemia activity at low doses, along with prolonged accumulation in tumors, undetectable systemic free payload, and favorable repeat-dose non-human primate findings supporting a manageable safety and tolerability profile.
Data from the second poster (Abstract Number: 1710) extend Orum’s previously presented findings by showing activity across primary AML patient samples and in models with relevant tumor mutations, including TP53. Taken together, the findings support the potential for broad activity in AML, including in patients with TP53 mutations.
“These AACR data are particularly encouraging in the context of AML, where many patients, especially those with TP53 mutations, continue to have limited treatment options and poor outcomes,” said Olaf Christensen, M.D., Chief Medical Officer of Orum. “The activity we are seeing across primary patient samples and TP53-relevant models, together with a consistent pharmacologic and tolerability profile, supports the continued advancement of ORM-1153 toward clinical development.”
Both posters are available on Orum’s website and will be presented at AACR on Monday, April 20, from 9 am to 12 pm PDT.
About ORM-1153
ORM-1153 is a CD123-targeting degrader-antibody conjugate developed using Orum’s Dual-Precision TPD²® approach. The molecule is built from two proprietary elements, a GSPT1-degrading payload and an anti-CD123 antibody engineered for high internalization efficiency, conjugated with a cleavable β-glucuronide linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.
About Orum’s TPD² Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum’s novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Daejeon, South Korea, and Lexington, MA, US. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the advancement of the ORM-1153 program to the clinical stage; the timing of regulatory submissions; the successful translation of preclinical and low-dose findings to clinical results and therapeutic dosage; the realization of intended design improvements; the potential indications for, and broad activity of, ORM-1153 and treatment of patients with TP53 mutations; the potential improvement of pharmacologic properties and the safety and tolerability profile; the potential success of the TPD² approach; and the development of additional novel payloads, are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
Appointments add clinical development, translational oncology, company-building, and strategic investment expertise as Orum advances its next wave of degrader-antibody conjugate programs
BOSTON, USA, and DAEJEON, South Korea, April 13, 2026 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board of Directors, following approval at the Company’s Annual General Meeting, which took place March 27, 2026. Orum is advancing GSPT1-directed TPD²® programs and developing novel degrader payloads to expand the potential of DACs in oncology and beyond.
“Maria and Geoff join Orum at an important point in the Company’s evolution,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “As we advance our next wave of DAC programs to the clinic and continue to broaden our payload capabilities, their perspectives will be highly valuable. Maria brings deep experience across oncology clinical development, translational medicine, biomarker strategy, and regulatory execution. Geoff brings a strong record in company building, partnering, and strategic transactions across the life sciences. Together, they strengthen our Board as we continue building Orum into a leading DAC company.”
“Orum has built a compelling approach to targeted protein degradation by combining the precision of antibodies with the catalytic potential of degrader payloads,” said Dr. Koehler. “I am pleased to join the Board as the company advances its DAC pipeline to the clinic, and I look forward to supporting the team as it works to translate this science into meaningful new therapeutic options for patients.”
“What stands out about Orum is that the company has established a differentiated position in DACs, with strong scientific foundations and multiple paths to value creation across its platform and pipeline,” said Mr. Meyerson. “I am excited to join the Board and support the management team as the company advances its programs, expands its strategic reach, and works to realize the broader potential of its technology.”
Dr. Koehler is an oncology biotech executive, hematologist/oncologist, and board director with more than 20 years of experience across clinical development, regulatory strategy, translational oncology, medical affairs, and biomarker-driven drug development. Most recently, she served as Venture Partner with Omega Funds and Senior Advisor to Viking Global, and until March 2025 was Chief Medical Officer of Repare Therapeutics, where she led clinical, regulatory strategy, and operations. She previously served as Chief Medical Officer of Bicycle Therapeutics and held senior oncology development roles at Pfizer, GSK, and AstraZeneca, including leadership of IBRANCE® (palbociclib) development at Pfizer. Dr. Koehler has played a prominent role in early oncology development and biomarker strategy, has authored more than 170 peer-reviewed publications and chapters, and has served on multiple public and private company boards, including Abdera Therapeutics, REMIX Therapeutics, Ikena, Silverback, and Celyad.
Mr. Meyerson is a life science entrepreneur, strategic advisor, and transaction leader with experience spanning biotech investment banking, business development, venture capital, and company creation. He is Co-founder and CEO of Locust Walk, and also Co-founder of Franklin Life Science, Venning Life Sciences, and BioBreak. He brings a broad perspective shaped by work across strategic transactions and company-building in the life sciences, with expertise in business development, M&A negotiations and deal structuring, venture capital investing, and growth strategy.
About Orum’s TPD² Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²) with the precision of antibody targeting to develop the next generation of degrader-antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum’s novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Daejeon, South Korea, and Lexington, MA, US. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the creation of a next wave of DAC programs, their advancement to the clinical stage, the broadening of Orum’s payload capabilities, and the development of new therapeutic options are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026
BOSTON, USA and DAEJEON, South Korea, March 17, 2026 – Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), today announced that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.
Orum’s two posters on ORM-1153 will highlight preclinical efficacy, pharmacology, and non-human primate safety findings that support advancement toward clinical development in AML.
“The data being presented at AACR reflect continued progress for ORM-1153 and Orum’s Dual-Precision TPD²® approach,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “These preclinical data, including repeat-dose non-human primate studies, support advancement toward clinical development and underscore the potential of our approach to expand the therapeutic window beyond conventional cytotoxic antibody-drug conjugates.”
Orum’s AACR 2026 Presentation Details
Both posters will be presented on Monday, April 20, from 9 am to 12 pm PDST.
ORM-1153: A Novel CD123-Targeting Degrader Antibody Conjugate with Proprietary GSPT1 Degrading Payload for the Treatment of Acute Myeloid Leukemia
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 7
Poster Number: 1710
ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC)
Session Category: Experimental and Molecular Therapeutics
Session Title: Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 12
Poster Number: 1824
Posters will be available on Orum’s website following the presentation.
About ORM-1153
ORM-1153 is a CD123-targeting degrader antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule conjugates a proprietary GSPT1-degrading payload to an anti-CD123 antibody with high internalization efficiency via a β-glucuronide cleavable linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.
About Orum’s TPD² Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the advancement of the ORM-1153 program to the clinical stage, the successful translation of preclinical findings to clinical results, the potential indications for ORM-1153, the expansion of the therapeutic window, and the potential success of the TPD² approach, are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs
BOSTON, USA and DAEJEON, South Korea, January 5, 2026 – Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation.
“Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “His leadership experience in ADCs, T-cell engagers, and structure-driven platform design aligns with Orum’s commitment to precision engineering the next generation of degrader-antibody conjugates. Chad’s expertise strengthens our position as a leader in DAC innovation and supports our progress toward meaningful clinical milestones.”
As CSO, Dr. May will provide scientific vision and R&D leadership, guiding the strategic direction, discovery, and advancement of Orum’s pipeline, including the continued evolution of the Company’s proprietary DAC platforms and programs. He will oversee scientific strategy across discovery, translational research, and preclinical development and will play a central role in shaping the next stage of Orum’s technology innovation and pipeline growth.
“The opportunity to join Orum at this stage of growth is incredibly compelling,” said Dr. May. “The Company’s Dual-Precision Targeted Protein Degradation approach provides a powerful foundation for creating new classes of degraders guided by antibody specificity. I am excited to work closely with the talented scientific and leadership teams to advance Orum’s DAC platforms, expand therapeutic applications across cancer and other serious diseases, and drive the next wave of innovation in degrader-antibody conjugates.”
Dr. May joins Orum from Serotiny, where he served as CSO and oversaw the advancement of a novel gene and cell therapy platform through the company’s post-acquisition integration into Johnson & Johnson. Previously, he served as Senior Vice President of Research and Development at Maverick Therapeutics, where he co-founded and built the R&D organization, advanced multiple conditionally active T-cell engager programs into clinical trials, and led the company’s build-to-buy collaboration with Takeda. Earlier in his career, Dr. May held scientific leadership roles at Pfizer, where he led teams developing T-cell engagers and ADCs and advanced several programs into IND-enabling studies and clinical development. His prior work at ImClone Systems involved the design, conjugation, and evaluation of antibody-based therapeutics. Over his career, Dr. May has built and led high-performing scientific teams, contributed to numerous first-in-class program nominations, and authored more than 30 publications and patents.
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.
Orum Therapeutics Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the development of new classes of degraders; the development of a next generation of degrader-antibody conjugates; the advancement of Orum’s pipeline, including DAC platforms and programs; the expansion of therapeutic applications; the advancement of programs to the clinical stage; and the achievement of clinical milestones are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: IR/PR, Orum Therapeutics, media@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., jessica@litldog.com